Fox Chase Cancer Center News

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

Fox Chase Cancer Center’s Anthony Villano, MD, FACS, Assistant Professor in the Department of Surgery, and Jeffrey Farma, MD, FACS, Chair of the Department of Surgery, are editors of a new textbook aimed at introducing surgical oncology trainees to important career concepts.

Fox Chase Cancer Center has once again been recognized among the nation’s leading institutions for cancer care in the 2025–2026 U.S. News & World Report Best Hospitals rankings.

Using a novel method to analyze tumor growth rates, researchers at Fox Chase Cancer Center have provided the most in-depth assessment to date of how fast breast cancers grow in patients and how surgical delays may affect breast cancer staging, which measures the extent of cancer spread in the body. The newly published study offers new insight into how tumors progress in the time between diagnosis and surgery.

MBCure, a nonprofit focused on metastatic breast cancer (MBC) research, awareness, education, and access efforts, is launching the MBCure Research Consortium with three of the world’s leading cancer institutions: Fox Chase Cancer Center, Penn Medicine’s Abramson Cancer Center, and Memorial Sloan Kettering Cancer Center (MSK).

Sanjeevani Arora, PhD, Assistant Professor in the Cancer Prevention and Control Research Program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, was recently recognized by the Journal of the American Medical Association (JAMA) Network Open for significant contributions in her role as a reviewer.

A new method of assessing workloads for clinical researchers at Fox Chase Cancer Center has proven effective in mitigating workload imbalances and improving phase 1 clinical programs. The findings of this project were presented at the Association of American Cancer Institutes’ (AACI) Clinical Research Innovation (CRI) Annual Meeting.

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research co-headed by a Fox Chase Cancer Center scientist helps explain why — and offers three strategies for making treatment more effective.